{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:59:30Z","timestamp":1781207970535,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Jakub hr. Potocki Foundation"},{"name":"National Science Centre, Poland","award":["N402 139738"],"award-info":[{"award-number":["N402 139738"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jsbmb.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T12:44:46Z","timestamp":1550148286000},"page":"48-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Imatinib inhibits the regrowth of human colon cancer cells after treatment with 5-FU and cooperates with vitamin D analogue PRI-2191 in the downregulation of expression of stemness-related genes in 5-FU refractory cells"],"prefix":"10.1016","volume":"189","author":[{"given":"Agnieszka","family":"Kotlarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Przybyszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Neska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mi\u0142oszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika Anna","family":"Grygorowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Kutner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiusz","family":"Markowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2019.02.003_bib0005","article-title":"Colorectal cancer","volume":"15065","author":"Kuipers","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","article-title":"CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway","volume":"27","author":"Ma","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0015","doi-asserted-by":"crossref","first-page":"e3077","DOI":"10.1371\/journal.pone.0003077","article-title":"Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties","volume":"3","author":"Levina","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jnci\/djn123","article-title":"Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy","volume":"100","author":"Li","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0025","doi-asserted-by":"crossref","first-page":"e2428","DOI":"10.1371\/journal.pone.0002428","article-title":"Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy","volume":"3","author":"Dylla","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-12-24","article-title":"Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden","volume":"12","author":"Abubaker","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0035","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7150\/ijbs.10248","article-title":"5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells","volume":"11","author":"Xu","year":"2015","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15283\/ijsc.2009.2.2.109","article-title":"Cancer stem cells and their mechanism of chemo-radiation resistance","volume":"2","author":"Kim","year":"2009","journal-title":"Int. J. Stem Cells"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0045","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/jcb.23199","article-title":"Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile","volume":"112","author":"Latifi","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0050","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1541-7786.MCR-12-0274","article-title":"Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma","volume":"10","author":"van der Horst","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0055","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.4161\/cc.21021","article-title":"Induction of cancer cell stemness by chemotherapy","volume":"11","author":"Hu","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0060","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1038\/ncomms3467","article-title":"Non-Darwinian dynamics in therapy-induced cancer drug resistance","volume":"4","author":"Pisco","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0065","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/bjc.2015.146","article-title":"Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse:\u2019 What does not kill me strengthens me\u2019","volume":"112","author":"Pisco","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2017.06.025","article-title":"Endocrine functions of vitamin D","volume":"453","author":"Carlberg","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0075","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd3318","article-title":"Vitamin D, disease and therapeutic opportunities, Nature reviews","volume":"9","author":"Plum","year":"2010","journal-title":"Drug Discov."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0080","series-title":"Extraskeletal Effects of Vitamin D","first-page":"115","article-title":"Vitamin D and leukaemia","author":"Brown","year":"2018"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072119","article-title":"Vitamins D: relationship between structure and biological activity","volume":"19","author":"Kutner","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0090","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1021\/acs.jmedchem.8b00337","article-title":"Aromatic-based design of highly active and noncalcemic vitamin d receptor agonists","volume":"61","author":"Gogoi","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0095","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3691","article-title":"The role of vitamin D in reducing cancer risk and progression","volume":"14","author":"Feldman","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3892\/or.2014.3247","article-title":"Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment","volume":"32","author":"Milczarek","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jsbmb.2015.08.025","article-title":"Synthesis and evaluation of geometric analogs of 1alpha,25-dihydroxyvitamin D2 as potential therapeutics","volume":"164","author":"Bolla","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jsbmb.2010.03.017","article-title":"Antitumor properties of (5E,7E) analogs of vitamin D3","volume":"121","author":"Filip","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jsbmb.2015.09.014","article-title":"Novel analogs of 1,25-dihydroxyvitamin D2 combined with a plant polyphenol as highly efficient inducers of differentiation in human acute myeloid leukemia cells","volume":"164","author":"Nachliely","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0120","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1007\/s13277-015-4311-4","article-title":"Differential interference of vitamin D analogs PRI-1906, PRI-2191, and PRI-2205 with the renewal of human colon cancer cells refractory to treatment with 5-fluorouracil","volume":"37","author":"Kotlarz","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060903","article-title":"The effect of analogues of 1alpha,25-Dihydroxyvitamin D(2) on the regrowth and gene expression of human Colon Cancer cells refractory to 5-Fluorouracil","volume":"17","author":"Neska","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0130","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: Multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0140","article-title":"Preparation of crystalline methanesulfonic acid addition salts of imatinib","author":"Szczepek","year":"2005","journal-title":"PTC Int. Appl."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0145","article-title":"A process for preparation of imatinib base","author":"Szczepek","year":"2006","journal-title":"PTC Int. Appl. WO"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0150","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/jps.23412","article-title":"Physicochemical characteristics of sunitinib malate and its process-related impurities","volume":"102","author":"Sidoryk","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0155","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3892\/or.2012.1886","article-title":"Studies on the mechanisms of superagonistic pro-differentiating activities of side-chain modified analogs of vitamin D2","volume":"28","author":"Baurska","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0160","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.steroids.2008.06.010","article-title":"Side-chain modified vitamin D analogs induce rapid accumulation of VDR in the cell nuclei proportionately to their differentiation-inducing potential","volume":"73","author":"Gocek","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0165","first-page":"4879","article-title":"The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy","volume":"62","author":"Attoub","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0170","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1002\/ijc.23029","article-title":"Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation","volume":"121","author":"Stahtea","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0175","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.12659\/MSM.898152","article-title":"Effects and mechanism of imatinib in inhibiting colon cancer cell proliferation","volume":"22","author":"Samei","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0180","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/cncr.22622","article-title":"Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial","volume":"109","author":"Al-Batran","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0185","first-page":"1251","article-title":"A phase I dose-escalation study of imatinib mesylate (Gleevec\/STI571) plus capecitabine (Xeloda) in advanced solid tumors","volume":"30","author":"Dugan","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0190","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/bjc.2013.553","article-title":"A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer","volume":"109","author":"Kelley","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00280-012-2009-5","article-title":"A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer","volume":"71","author":"Michael","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0200","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00005-016-0391-0","article-title":"Imatinib inhibits the renewal and tumorigenicity of CT-26 Colon Cancer cells after cytoreductive treatment with doxorubicin","volume":"65","author":"Przybyszewska","year":"2017","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0205","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.2012.45.1930","article-title":"Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial","volume":"31","author":"Carrato","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdr046","article-title":"A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer","volume":"23","author":"Starling","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0215","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/j.1349-7006.2012.02320.x","article-title":"First-line sunitinib plus FOLFIRI in Japanese patients with unresectable\/metastatic colorectal cancer: a phase II study","volume":"103","author":"Tsuji","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0220","doi-asserted-by":"crossref","first-page":"24873","DOI":"10.3390\/ijms161024873","article-title":"Antiproliferative activity and in vivo toxicity of double-point modified analogs of 1,25-Dihydroxyergocalciferol","volume":"16","author":"Trynda","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0225","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000066241","article-title":"Influence of tacalcitol on cell cycle kinetics of human keratinocytes following standardized injury","volume":"12","author":"Mommers","year":"1999","journal-title":"Skin Pharmacol. Appl. Skin Physiol."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0230","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.3892\/mmr.2014.3074","article-title":"Inhibitory effects of imatinib on vitamin D(3) synthesis in human keratinocytes","volume":"11","author":"Mehlig","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0235","doi-asserted-by":"crossref","first-page":"CR721","DOI":"10.12659\/MSM.883599","article-title":"Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"Jaeger","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.jsbmb.2019.02.003_bib0240","doi-asserted-by":"crossref","first-page":"27191","DOI":"10.3390\/ijms161126016","article-title":"Vitamin D analogs potentiate the antitumor effect of imatinib mesylate in a human A549 lung tumor model","volume":"16","author":"Maj","year":"2015","journal-title":"Int. J. Mol. Sci."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076018303340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076018303340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:49Z","timestamp":1760745649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076018303340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":48,"alternative-id":["S0960076018303340"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2019.02.003","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib inhibits the regrowth of human colon cancer cells after treatment with 5-FU and cooperates with vitamin D analogue PRI-2191 in the downregulation of expression of stemness-related genes in 5-FU refractory cells","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}